Phase 2 RCT | Biomarker-selected maintenance Poly ADP-Ribose Polymerase inhibition with Rucaparib following chemotherapy for metastatic urothelial carcinoma. 15 Aug, 2022 | 11:42h | UTC A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma – Journal of Clinical Oncology